非血管ステントの世界市場分析および予測...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 13
1.2 List of Figures 18
2 Introduction 22
2.1 Catalyst 23
2.2 Related Reports 23
3 Industry Overview 24
3.1 Overview 24
3.2 Non-Vascular Stenting Indications 25
3.2.1 Enteral Stents 25
3.2.2 Pancreatic and Biliary Stents 26
3.2.3 Airway Stents 27
3.2.4 Urinary Tract Stents 29
3.3 Types of Stents and Clinical Efficacy 30
3.3.1 Enteral Stents 30
3.3.2 Pancreatic and Biliary Stents 34
3.3.3 Airway Stents 36
3.3.4 Urinary Tract Stents 37
3.4 Procedure Trends 37
3.4.1 US 37
3.4.2 5EU 47
3.4.3 Asia-Pacific 56
3.4.4 South America 66
3.5 Market Access 74
3.5.1 Product Adoption 75
3.5.2 Regulation 82
3.5.3 Reimbursement 88
3.6 Regulatory Issues/Recalls (2011-2014) 98
3.6.1 Cordis Corporation Class II Recall of S.M.A.R.T Control Transhepatic Biliary Stent 98
3.7 Mergers, Acquisitions, and Other Deals 99
3.7.1 Medtronic Acquires Covidien 99
3.7.2 Beijing King Health Signs Distribution Agreement With Allium Medical 99
3.7.3 Cordis Acquires Flexible Stenting Solutions 99
3.7.4 Allium Medical Enters Into Distribution Agreement With Meizler UCB Biopharma 99
3.7.5 Gore and ConMed Extend Distribution Agreement 100
3.7.6 Allium Medical Acquires Gardia Medical 100
3.7.7 Flexible Stenting Solutions Raises Funds in Series B Financing 100
3.8 Economic Impact 100
4 Unmet Needs 103
4.1 Addressing the Complications 103
4.1.1 Enteral Stents 103
4.1.2 Pancreatic and Biliary Stents 104
4.1.3 Airway Stents 105
4.1.4 Urinary Tract Stents 105
4.2 Overcoming Stent Design Challenges 106
4.2.1 Stent Shortening 106
4.2.2 Stent Fracture 107
4.2.3 Flexibility 107
4.3 Simplify Delivery Systems 108
4.4 Disconnect Between Industry and Physicians 108
4.5 Indication-Specific Stents 109
4.6 Lack of Long-Term and Comparative Clinical Data 110
4.7 Refocus on Pipeline Products 111
4.8 Lack of Standardization 112
4.9 Cost-Containment 112
4.10 Need for An International Procedure Registry 113
5 Market Opportunity Analysis 115
5.1 Improve Stent Systems 115
5.2 Biodegradable Stents 115
5.3 Drug-Eluting Stents 119
5.4 Radiosensitization 121
5.5 Customized Stents 122
5.6 Emerging Markets 123
6 Market Drivers and Barriers 124
6.1 Driver: Rising Disease Prevalence 124
6.1.1 Cancer 124
6.1.2 Urolithiasis 125
6.2 Driver: Non-Malignant Stenting Applications to Drive the Market 125
6.2.1 Drainage 125
6.2.2 Bariatric Surgery 126
6.2.3 Neoadjuvant Treatment 127
6.2.4 Benign Strictures 128
6.3 Driver: Fully-Covered, Removable Metal Stents To Drive Future Growth 128
6.4 Driver: Preference for Minimally-Invasive Solutions 130
6.5 Driver: Increased Life Expectancy 130
6.6 Driver: Technological Advancements 131
6.7 Driver: Patient Demand and Awareness 132
6.8 Driver: Rising Competition and Innovation 133
6.9 Barrier: Availability of Venture Capital 133
6.10 Barrier: Burden of Rising Regulation 134
6.11 Barrier: Proving Long-Term Efficacy 135
6.12 Barrier: Medical Device Excise Tax 135
7 Competitive Assessment 137
7.1 Gastrointestinal Stents 137
7.1.1 Overview 137
7.1.2 WallFlex (Boston Scientific Corporation) 137
7.1.3 Evolution (Cook Medical) 139
7.1.4 Niti-S (Taewoong Medical) 141
7.1.5 Other Key Marketed Gastrointestinal Stents 144
7.2 Biliary Stents 145
7.2.1 Overview 145
7.2.2 WallFlex Biliary RX (Boston Scientific Corporation) 145
7.2.3 Cotton-Leung (Amsterdam) (Cook Medical) 148
7.2.4 Bonastent (EndoChoice) 149
7.2.5 Other Key Marketed Biliary Stents 151
7.3 Airway Stents 153
7.3.1 Overview 153
7.3.2 Dumon (Novatech) 153
7.3.3 Aero/Aero DV (Merit Endotek) 154
7.3.4 Ultraflex (Boston Scientific Corporation) 156
7.3.5 Other Key Marketed Airway Stents 158
7.4 Urinary Tract Stents 158
7.4.1 Overview 158
7.4.2 Polaris Ultra (Boston Scientific Corporation) 158
7.4.3 InLay Optima (C.R. Bard) 160
7.4.4 Other Key Marketed Urinary Tract Stents 161
8 Clinical Trials to Watch 162
8.1 Overview 162
8.2 Enteral Stents 162
8.3 Pancreatic and Biliary Stents 164
8.4 Airway Stents 165
8.5 Urinary Tract Stents 165
9 Current and Future Players 166
9.1 Trends in Corporate Strategy 166
9.2 Company Profiles 168
9.2.1 Allium Medical 168
9.2.2 Boston Scientific Corporation 170
9.2.3 ConMed 174
9.2.4 Cook Medical 177
9.2.5 C.R. Bard 179
9.2.6 Ella-CS 182
9.2.7 Merit Endotek 184
9.2.8 M.I. Tech 187
9.2.9 Micro-Tech (Nanjing) 188
9.2.10 Medtronic (Covidien) 191
9.2.11 Novatech 193
9.2.12 Olympus 195
9.2.13 Taewoong Medical 198
9.2.14 Xlumena 200
9.2.15 Other Companies 203
10 Market Outlook 205
10.1 Company Market Share 205
10.1.1 US 205
10.1.2 5EU 206
10.1.3 South America 207
10.1.4 Asia-Pacific 208
10.2 By Market Segment 209
10.2.1 Global Overview 209
10.2.2 Enteral Stents 211
10.2.3 Pancreatic and Biliary Stents 212
10.2.4 Airway Stents 214
10.2.5 Urinary Tract Stents 215
10.3 By Geography 217
10.3.1 Global Overview 217
10.3.2 US 219
10.3.3 EU 222
10.3.4 South America 239
10.3.5 Asia-Pacific 242
11 Appendix 254
11.1 Bibliography 254
11.2 Abbreviations 271
11.3 Research Methodology 276
11.3.1 Overview 276
11.3.2 Coverage 276
11.3.3 Secondary Research 276
11.4 Physicians and Specialists Included in this Study 278
11.5 Primary Research 281
11.5.1 Primary Research – Key Opinion Leader Interviews 281
11.5.2 Primary Research – Physician and Industry Interviews 282
11.5.3 Expert Panel Validation 283
11.6 Forecasting Methodology 284
11.7 About the Authors 285
11.7.1 Analysts 285
11.7.2 Global Head of Healthcare 286
11.8 About MediPoint 287
11.9 About GlobalData 287
11.10 Disclaimer 287